Haverkamp W, Israel C, Parwani A
Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.
Klinik für Kardiologie, Nephrologie und Diabetologie, Evangelisches Klinikum Bethel, Bielefeld, Deutschland.
Herzschrittmacherther Elektrophysiol. 2017 Sep;28(3):307-316. doi: 10.1007/s00399-017-0516-0.
Amiodarone has multiple and complex electrophysiological effects that render it a very effective antiarrhythmic drug for the treatment of both, supraventricular and ventricular arrhythmias. Proarrhythmic effects of amiodarone in patients with structural heart disease are rare. However, extracardiac adverse effects occurring in association with amiodarone treatment are frequent and feared. These adverse effects have usually been related to total amiodarone exposure (i. e., dose and duration of treatment). Parallel to a more frequent use of lower amiodarone maintenance doses (100-200 mg/day), the incidence of severe unwanted extracardiac side effects has decreased. High-dose maintenance regiments (daily dose ≥300 mg) are usually obsolete. This paper discusses recommendations regarding the monitoring of cardiac and extracardiac side effects of amiodarone. They need to be regarded by physicians using amiodarone to ensure long-term safety of amiodarone therapy.
胺碘酮具有多种复杂的电生理效应,使其成为治疗室上性和室性心律失常的非常有效的抗心律失常药物。胺碘酮在结构性心脏病患者中的促心律失常作用罕见。然而,与胺碘酮治疗相关的心脏外不良反应却很常见且令人担忧。这些不良反应通常与胺碘酮的总暴露量(即治疗剂量和持续时间)有关。随着较低剂量胺碘酮维持剂量(100 - 200毫克/天)的更频繁使用,严重的心脏外不良副作用的发生率有所下降。高剂量维持方案(每日剂量≥300毫克)通常已过时。本文讨论了关于胺碘酮心脏和心脏外副作用监测的建议。使用胺碘酮的医生需要重视这些建议,以确保胺碘酮治疗的长期安全性。